1152475-40-5

Basic information

• Product Name: 2-Chloro-7-iodothieno[3,2-d]pyrimidine
• Synonyms: 2-Chloro-7-iodothieno[3,2-d]pyrimidine
• CAS NO: 1152475-40-5
• Molecular Formula: C₆H₂ClIN₂S
• Molecular Weight: 296.51595
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 1152475-40-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-Chloro-7-iodothieno[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-7-iodothieno[3,2-d]pyrimidine(1152475-40-5)
• EPA Substance Registry System: 2-Chloro-7-iodothieno[3,2-d]pyrimidine(1152475-40-5)

Safety Data

• Hazardous Substances Data: 1152475-40-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-7-iodothieno[3,2-d]pyrimidine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new drugs with potential therapeutic applications.
Used in Research Applications:
2-Chloro-7-iodothieno[3,2-d]pyrimidine is used as a research compound to study the properties and reactions of thienopyrimidines. This helps in understanding their potential applications in various fields, including medicine and materials science.

Upstream product

• 1119280-68-0 2-chlorothieno[3,2-d]pyrimidine 
• 16234-14-3 2,4-dichlorothieno[3,2-d]pyrimidine 

Downstream Products

• 1152473-40-9 7-iodo-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine 
• 1152473-78-3 7-iodo-N-(3-nitrophenyl)thieno[3,2-d]pyrimidin-2-amine 

Relevant articles and documents

Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors

A series of 2,7-disubstituted-thieno[3,2-d]pyrimidine derivatives were designed, synthesized and evaluated as novel focal adhesion kinase (FAK) inhibitors. The novel 2,7-disubstituted-thieno[3,2-d]pyrimidine scaffold has been designed as a new kinase inhibitor platform that mimics the bioactive conformation of the well-known diaminopyrimidine motif. Most of the compounds potently suppressed the enzymatic activities of FAK and potently inhibited the proliferation of U-87MG, A-549 and MDA-MB-231 cancer cell lines. Among these derivatives, the optimized compound 26f potently inhibited the enzyme (IC50 = 28.2 nM) and displayed stronger potency than TAE-226 in U-87MG, A-549 and MDA-MB-231 cells, with IC50 values of 0.16, 0.27, and 0.19 μM, respectively. Compound 26f also exhibited relatively less cytotoxicity (IC50 = 3.32 μM) toward a normal human cell line, HK2. According to the flow cytometry results, compound 26f induced the apoptosis of MDA-MB-231 cells in a dose-dependent manner and effectively arrested MDA-MB-231 cells in G0/G1 phase. Further investigations revealed that compound 26f potently suppressed the migration of MDA-MB-231 cells. Collectively, these data support the further development of compound 26f as a lead compound for FAK-targeted anticancer drug discovery.

N-CONTAINING HETEROCYCLIC COMPOUNDS

The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.